Fidelis Animal Health is classified as operating in the Pharmaceutical Preparation Manufacturing industry, NAICS Code 325412.
Trademark Applications
Trademark applications show the products and services that Fidelis Animal Health is developing and marketing.
Fidelis Animal Health doesn't have any recent trademark applications, indicating Fidelis Animal Health is focusing on
its existing business rather than expanding into new products and markets.
Trademarks may include brand names, product names, logos and slogans.
Trademark
Date
FIDELIS Analgesic preparations; Pharmaceutical preparations for the treatment of animals
06/13/2022
ETHIQA XR Pharmaceutical preparations, namely, buprenorphine extended release injectable suspension to provide analgesia for laboratory animals
11/30/2017
ETHIQA XR (BUPRENORPHINE EXTENDED-RELEASE INJECTABLE SUSPENSION) 1.3 MG/ML Pharmaceutical preparations, namely, buprenorphine extended release injectable suspension to provide analgesia for laboratory animals
11/30/2017
See all trademarks and details in the Full Report.
Market Share of Fidelis Animal Health's Largest Competitors
A competitive analysis shows these companies are in the same general field as Fidelis Animal Health, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Fidelis Animal Health.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as Fidelis Animal Health and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.